Chemotherapy for Stage II Colon Cancer

Clinics in Colon and Rectal Surgery

Volumn 28, Issue 4, 2015, Pages 256-261

  Varghese, Anna ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

adjuvant therapy; chemotherapy; stage II colon cancer

Indexed keywords

EID: 84947927813     PISSN: 15310043     EISSN: 15309681     Source Type: Journal    
DOI: 10.1055/s-0035-1564430     Document Type: Article

References (32)

1. Moertel C. G., Fleming T. R., Macdonald J. S., et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med: 1995; 122 5 321 326
2. André T., Boni C., Mounedji-Boudiaf L., et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med: 2004; 350 23 2343 2351
3. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2015. CA Cancer J Clin: 2015; 65 5 29
4. Gunderson L. L., Jessup J. M., Sargent D. J., Greene F. L., Stewart A. K. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol: 2010; 28 2 264 271
5. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol: 1999; 17 5 1356 1363
6. Gill S., Loprinzi C. L., Sargent D. J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol: 2004; 22 10 1797 1806
7. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, National Comprehensive Cancer Network Colon Cancer (Version 3, 2015). http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf. Accessed September 9, 2015
8. Benson A. B. III, Schrag D., Somerfield M. R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol: 2004; 22 16 3408 3419
9. Labianca R., Nordlinger B., Beretta G. D., et al. ESMO Guidelines Working Group. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol: 2013; 24 06 vi64 vi72
10. Schrag D., Rifas-Shiman S., Saltz L., Bach P. B., Begg C. B. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol: 2002; 20 19 3999 4005
11. Wolmark N., Fisher B., Rockette H., et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst: 1988; 80 1 30 36
12. Wolmark N., Rockette H., Wickerham D. L., et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol: 1990; 8 9 1466 1475
13. Wolmark N., Rockette H., Fisher B., et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol: 1993; 11 10 1879 1887
14. Wolmark N. RH, Rockette H., Mamounas E. P., et al. The relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU+levamisole (FU-LEV), and 5-FU + leucovorin + levamisole (FU-LV-LEV) in patients with Dukes' B and C carcinoma of the colon. Proc Am Soc Clin Oncol: 1996; 15 205
15. Mamounas E., Wieand S., Wolmark N., et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol: 1999; 17 5 1349 1355
16. Harrington D. P. The tea leaves of small trials. J Clin Oncol: 1999; 17 5 1336 1338
17. Gray R., Barnwell J., McConkey C., Hills R. K., Williams N. S., Kerr D. J.; Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet: 2007; 370 9604 2020 2029
18. André T., Boni C., Navarro M., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol: 2009; 27 19 3109 3116
19. Tournigand C., André T., Bonnetain F., et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol: 2012; 30 27 3353 3360
20. Kuebler J. P., Wieand H. S., O'Connell M. J., et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol: 2007; 25 16 2198 2204
21. Yothers G., O'Connell M. J., Allegra C. J., et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol: 2011; 29 28 3768 3774
22. O'Connor E. S., Greenblatt D. Y., LoConte N. K., et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol: 2011; 29 25 3381 3388
23. Hutchins G., Southward K., Handley K., et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol: 2011; 29 10 1261 1270
24. Ribic C. M., Sargent D. J., Moore M. J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med: 2003; 349 3 247 257
25. Sargent D. J., Marsoni S., Monges G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol: 2010; 28 20 3219 3226
26. Ng K., Schrag D. Microsatellite instability and adjuvant fluorouracil chemotherapy: a mismatch? J Clin Oncol: 2010; 28 20 3207 3210
27. Kim S. T., Lee J., Park S. H., et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol: 2010; 66 4 659 667
28. Iwashyna T. J., Lamont E. B. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol: 2002; 20 19 3992 3998
29. Sargent D. J., Goldberg R. M., Jacobson S. D., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med: 2001; 345 15 1091 1097
30. Gray R. G., Quirke P., Handley K., et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol: 2011; 29 35 4611 4619
31. Kennedy R. D., Bylesjo M., Kerr P., et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol: 2011; 29 35 4620 4626
32. Salazar R., Roepman P., Capella G., et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol: 2011; 29 1 17 24